Efficacy & safety evaluation of Ayurvedic treatment (Ashwagandha powder & Sidh Makardhwaj) in rheumatoid arthritis patients: a pilot prospective study.
Within the conventional system of medication in India Ashwagandha powder and Sidh Makardhwaj have been used for the therapy of rheumatoid arthritis. Nonetheless, security and efficacy of this therapy haven’t been evaluated. Due to this fact, the current examine was carried out to guage the efficacy and security of Ayurvedic therapy (Ashwagandha powder and Sidh Makardhwaj) in sufferers with rheumatoid arthritis.
METHODS
100 and twenty 5 sufferers with joint ache have been screened at an Ayurvedic hospital in New Delhi, India. Eighty six sufferers happy inclusion standards and have been included within the examine. Detailed medical historical past and bodily examination have been recorded. Sufferers took 5g of Ashwagandha powder twice a day for 3 weeks with lukewarm water or milk. Sidh Makardhwaj (100 mg) with honey was administered day by day for the following 4 weeks. The observe up of sufferers was carried out each two weeks. The first efficacy finish level was primarily based on American Faculty of Rheumatology (ACR) 20 response. Secondary finish factors have been ACR50, ACR70 responses, change from baseline in illness exercise rating (DAS) 28 rating and ACR parameters. Security assessments have been hepatic perform [alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), bilirubin and ß2 microglobulin], renal perform (urea and creatinine and NGAL) exams and urine mercury degree.
RESULTS
The examine was accomplished by 90.7 per cent (78/86) sufferers. Sufferers with average and excessive illness exercise have been 57.7 per cent (45/78) and 42.three per cent (33/78), respectively. All sufferers have been examined optimistic for rheumatoid issue and elevated ESR degree. Ashwagandha and Sidh Makardhwaj therapy decreased RA issue. A major change in post-treatment scores of tender joint counts, swollen joint counts, doctor international evaluation rating, affected person international evaluation rating, ache evaluation rating, affected person self assessed incapacity index rating and ESR degree have been noticed as in comparison with baseline scores. ACR20 response was noticed in 56.four per cent (44/78) sufferers (American Faculty of Rheumatology standards) and average response in 39.74 per cent (31/78) sufferers [European League Against Rheumatism (EULAR) criteria]. Ayurvedic therapy for seven weeks in rheumatoid arthritis sufferers confirmed regular kidney and liver perform exams. Nonetheless, elevated urinary mercury ranges have been was noticed after therapy.
CONCLUSIONS
The findings of the current examine counsel that this Ayurvedic therapy (Ashwagandha powder and Sidh Makardhwaj) has a possible for use for the therapy of rheumatoid arthritis. Nonetheless, resulting from small pattern measurement, quick length, non randomization and lack of a management group as examine limitations, additional research should be achieved to verify these findings.
Ayurpharmacoepidemiology en Path to Safeguarding Security and Efficacy of Ayurvedic Medication in International Outlook.
Ayurpharmacoepidemiology is a brand new area developed by synergy of the fields of scientific pharmacology, epidemiology, and ayurveda. It should use the consequences of ayurvedic medicinal merchandise on giant populations to explain and analyze the practices, consider the protection and efficacy, and perform medicoeconomic evaluations. Good pharmacoepidemiology practices in ayurveda is projected to help with problems with ayurpharmacoepidemiologic analysis.
The embraced good pharmacoepidemiology practices guideline on this viewpoint will have the ability to present invaluable proof in regards to the well being results of ayurvedic herbs/medication and think about totally different fields like pharmacovigilance, pharmacoeconomics, and drug discovery with ayurvedic reverse pharmacology strategy, additionally cross out vital knowledge for additional primary sciences examine in ayurveda biology, ayurgenomics, ayurnutrigenomics, and programs biology. A number of unanswered questions on ayurvedic drug use and knowledgeable interventions or insurance policies that may be addressed by informatics database, which is able to ultimately exhibit the credibility and rationality of ayurceuticals sooner or later.
Efficacy & safety evaluation of Ayurvedic treatment (Ashwagandha powder & Sidh Makardhwaj) in rheumatoid arthritis patients: a pilot prospective study.
[Computer evaluation of hidden potential of phytochemicals of medicinal plants of the traditional Indian ayurvedic medicine].
Applicability of our laptop applications PASS and PharmaExpert to prediction of organic exercise spectra of quite complicated and structurally numerous phytocomponents of medicinal crops, each individually and in mixtures has been evaluated. The online-resource on phytochemicals of 50 medicinal crops utilized in Ayurveda was created for the examine of hidden therapeutic potential of Conventional Indian Drugs (TIM) . It incorporates info on 50 medicinal crops, their utilizing in TIM and their pharmacology actions, additionally as 1906 phytocomponents.
PASS coaching set was up to date by addition of details about 946 pure compounds; then the coaching process and validation have been carried out, to estimate the standard of PASS prediction. It was proven that the distinction between the typical accuracy of prediction obtained in leave-5%-out cross-validation (94,467%) and in leave-one-out cross-validation (94,605%) may be very small. These outcomes confirmed excessive predictive capability of this system. Outcomes of organic exercise spectra prediction for all phytocomponents included in our database are in good correspondence with the experimental knowledge. Extra sorts of organic exercise predicted with excessive chance present the details about most promising instructions of additional research.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Canine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Canine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: The protein encoded by this gene is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
Description: A polyclonal antibody against LIF. Recognizes LIF from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:10000, IHC:1:25-1:100
Description: A polyclonal antibody against LIF. Recognizes LIF from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000
Description: LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation.
Description: LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation.
Description: Description of target: LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.039 ng/mL
Description: Description of target: Leukemia inhibitory factor, or LIF, is an interleukin 6 class cytokine that affects cell growth by inhibiting differentiation. When LIF levels drop, the cells differentiate. The LIF was mapped gene to 22q11-q12.2 by Southern analysis of a series of mouse/human somatic cell hybrids and by in situ hybridization to the chromosomes of 2 normal males and some individuals with chromosomal rearrangements. The gene maps between the Philadelphia translocation BCR1 and the breakpoint of the translocation in cell line GM2324 at 22q12.2. LIF derives its name from its ability to induce the terminal differentiation of myeloid leukemic cells, thus preventing their continued growth. Other properties attributed to the cytokine include: the growth promotion and cell differentiation of different types of target cells, influence on bone metabolism, cachexia, neural development, embryogenesis and inflammation.;Species reactivity: Mouse;Application: ELISA;Assay info: ;Sensitivity: <10pg/ml
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse LIF in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody for detection of LIF from Human. This LIF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human LIF
Description: A polyclonal antibody for detection of LIF from Human. This LIF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human LIF
Description: A polyclonal antibody for detection of LIF from Human. This LIF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human LIF
Description: LIF is a pleiotrophic factor produced by multiple cell types, including T cells, myelomonocytic lineages, fibroblasts, liver, heart and melanoma. LIF promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Other activities include the stimulation of acute phase protein synthesis by hepatocytes, stimulation of differentiation of cholinergic nerves, and suppression of adipogenesis by inhibiting the lipoprotein lipase in adipocytes. While human LIF is active on mouse cells and is widely used in the maintenance of murine ESC to prevent spontaneous differentiation, mouse LIF is not active on human cells due to its inability to bind to the human LIF receptor. Recombinant Murine LIF is a 19.9 kDa protein containing 180 amino acids residues, including three disulfide bonds.
Description: LIF is a pleiotrophic factor produced by multiple cell types, including T cells, myelomonocytic lineages, fibroblasts, liver, heart and melanoma. LIF promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Other activities include the stimulation of acute phase protein synthesis by hepatocytes, stimulation of differentiation of cholinergic nerves, and suppression of adipogenesis by inhibiting the lipoprotein lipase in adipocytes. While human LIF is active on mouse cells and is widely used in the maintenance of murine ESC to prevent spontaneous differentiation, mouse LIF is not active on human cells due to its inability to bind to the human LIF receptor. Recombinant Human LIF is a 19.7 kDa protein containing 180 amino acid residues, including three disulfide bonds.
Description: Leukemia inhibitory factor, or LIF, an interleukin 6 class cytokine, is a protein in cells that affects cell growth and development.Leukemia Inhibitory Factor has several functions such as cholinergic neuron differentiation, control of stem cell pluripotency, bone & fat metabolism, mitogenesis of factor dependent cell lines & promotion of megakaryocyte production in vivo. Removal of LIF pushes stem cells toward differentiation, but they retain their proliferative potential or pluripotency. Therefore LIF is used in mouse embryonic stem cell culture. It is necessary to maintain the stem cells in an undifferentiated state, however genetic manipulation of embryonic stem cells allows for LIF independent growth, notably overexpression of the gene Nanog. LIF is not required for culture of human embryonic stem cells.
Description: LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities also include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation and the stimulation of acute-phase protein synthesis in hepatocytes. LIF activates JAK & STAT signaling in human embryonic stem (ES) cells, but this pathway does not maintain pluripotency in these cells, which instead rely on FGF2-mediated ERK signaling. By contrast, mouse ES cells can be maintained by LIF-mediated JAK & STAT signaling. LIF binds to a high affinity heterodimeric receptor complex consisting of two proteins: LIF-R alpha that binds LIF with low affinity and the 130kDa (gp130) subunit that by itself does not bind LIF, but is required for high affinity binding of LIF.
Description: Leukemia Inhibitory Factor (LIF) is a lymphoid factor that promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. LIF has a number of other activities including cholinergic neuron differentiation, control of stem cell pluripotency, bone and fat metabolism, mitogenesis of certain factor dependent cell lines and promotion of megakaryocyte production in vivo. Human and murine mature LIF exhibit a 78% sequence identity at the amino acid level. Human LIF is equally active on human and mouse cells. Murine LIF is approximately 1000 fold less active on human cells than human LIF.
Description: Mouse Leukemia inhibitory factor（lif）is a secreted protein which belongs to the LIF/OSM family.LIF has been implicated in a many physiological processes including development, hematopoiesis, bone metabolism, and inflammation. it has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes.
Description: LIF is a pleiotrophic factor produced by multiple cell types including T cells, myelomoncytic lineages, fibroblasts, liver, heart and melanoma. LIF promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Other activities include the stimulation of acute phase protein synthesis by hepatocytes, stimulation of differentiation of cholinergic nerves, and suppression of adipogenesis by inhibiting the lipoprotein lipase in adipocytes. While human LIF is active on mouse cells and is widely used in the maintenance of murine ESC to prevent spontaneous differentiation, mouse LIF is not active on human cells due to its inability to bind to the human LIF receptor. Recombinant human LIF is a 19.6 kDa protein containing 180 amino acids residues including three disulfide bonds.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF (Internal). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF (Center). This antibody is tested and proven to work in the following applications:
The evaluation of prediction outcomes of units of phytocomponents in every of 50 medicinal crops was made by PharmaExpert software program. Based mostly on this evaluation, we discovered that the mix of phytocomponents from Passiflora incarnata might exhibit nootropic, anticonvulsant and antidepressant results. Experiments carried out in mice fashions confirmed the expected results of Passiflora incarnata extracts.
by 
